tbuckley/cabot-search huggingface dataset:
MA04.05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%
Authors: E. Jimenez Alguilar, J. Gainor, S. Kravets, S. Khosrowjerdi, C. Lydon, A. Adeni, S. Subegdjo, H. Rizvi, M. Hellmann, M. Awad
Journal: Journal of Thoracic Oncology (2018)
P1.04-15 Computerized Tomography Texture Analysis as Biomarker of Benefit from Nivolumab in Advanced Non-Small Cell Lung Cancer
Authors: C. Genova, E. Barabino, G. Ficarra, M. Verda, E. Rijavec, G. Rossi, M. Tagliamento, F. Biello, G. Barletta, M.G. Dal Bello, G. Cittadini, F. Grossi
Journal: Journal of Thoracic Oncology (2018)
MTE01.02 Lung Patient Derived Xenograft and Organoid
Authors: N. Moghal, N. Pham, R. Shi, N. Radulovich, M. Li, V. Raghavan, Q. Li, D. Wang, J. Tong, C. Zhu, L. Li, E. Stewart, L. Tamblyn, J. Weiss, S. Martins-Filho, D. Ravi, M. Pintilie, M. Moran, G. Liu, N. Leighl, F. Shepherd, M. Tsao
Journal: Journal of Thoracic Oncology (2018)
MA20.02 “Reduced” HUNT Lung Cancer Model for Predicting Lung Cancer in the Prospective Danish Lung Cancer Screening Study - Comparison with the NLST
Authors: O. Røe, M. Markaki, I. Tsmardinos, V. Lagani, J. Pedersen, Z. Saghir, H. Ashraf
Journal: Journal of Thoracic Oncology (2018)
A multicenter retrospective investigation on the efficacy of perioperative oral management in cancer patients
Authors: S.-I. Yamada, S. Soutome, T. Hasegawa, I. Toujou, H. Nakahara, M. Kawakami, M. Hirose, S. Fujita, T. Komori, T. Kirita, Y. Shibuya, M. Umeda, H. Kurita
Journal: Annals of Oncology (2018)
A High-Throughput Screen Identifies DYRK1A Inhibitor ID-8 that Stimulates Human Kidney Tubular Epithelial Cell Proliferation
Authors: Maria B. Monteiro, Susanne Ramm, Vidya Chandrasekaran, Sarah A. Boswell, Elijah J. Weber, Kevin A. Lidberg, Edward J. Kelly, Vishal S. Vaidya
Journal: Journal of the American Society of Nephrology (2018)

Background The death of epithelial cells in the proximal tubules is thought to be the primary cause of AKI, but epithelial cells that survive kidney injury have a remarkable ability to proliferate. Because proximal tubular epithelial cells play a predominant role in kidney regeneration after damage, a potential approach to treat AKI is to discover regenerative therapeutics capable of stimulating proliferation of these cells. Methods We conducted a high-throughput phenotypic screen using 1902 biologically active compounds to identify new molecules that promote proliferation of primary human proximal tubular epithelial cells in vitro . Results The primary screen identified 129 compounds that stimulated tubular epithelial cell proliferation. A secondary screen against these compounds over a range of four doses confirmed that eight resulted in a significant increase in cell number and incorporation of the modified thymidine analog EdU (indicating actively proliferating cells), compared with control conditions. These eight compounds also stimulated tubular cell proliferation in vitro after damage induced by hypoxia, cadmium chloride, cyclosporin A, or polymyxin B. ID-8, an inhibitor of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), was the top candidate identified as having a robust proproliferative effect in two-dimensional culture models as well as a microphysiologic, three-dimensional cell culture system. Target engagement and genetic knockdown studies and RNA sequencing confirmed binding of ID-8 to DYRK1A and upregulation of cyclins and other cell cycle regulators, leading to epithelial cell proliferation. Conclusions We have identified a potential first-in-class compound that stimulates human kidney tubular epithelial cell proliferation after acute damage in vitro .
Impact of invasive lobular carcinoma in Latin American breast cancer patients’ disease-free survival: The new paradox
Authors: D. Flores-Díaz, C. Arce Salinas, L. Flores, F. Lara, J.A. Matus Santos, J.E. Bargallo Rocha, V. Perez, N. Reynoso-Noveron, P.A. Cabrera, A. Mohar
Journal: Annals of Oncology (2018)
Health-related quality of life priorities in adolescents and young adults (AYA) with cancer: Discrepancies with health care professionals’ perceptions
Authors: S.E.J. Kaal, J.B. Prins, R. Jansen, E. Manten-Horst, P. Servaes, W.T.A. van der Graaf, O. Husson
Journal: Annals of Oncology (2018)
P2.01-37 A Ph 1/2 Study of Oral Selective AXL Inhibitor Bemcentinib (BGB324) with Docetaxel in pts with Previously Treated NSCLC
Authors: S. Rashdan, J. Williams, P. Currykosky, F. Fattah, J. Padro Arroyo, R. Smith, R. Holt, R. Brekken, D. Gerber
Journal: Journal of Thoracic Oncology (2018)
Long-term Outcomes of Autologous Peripheral Blood Stem Cell Transplantation in Patients With Cirrhosis
Authors: Changcun Guo, Guanya Guo, Xia Zhou, Yu Chen, Zheyi Han, Caifeng Yang, Shimin Zhao, Hongling Su, Zhexiong Lian, Patrick S.C. Leung, M. Eric Gershwin, Xinmin Zhou, Ying Han
Journal: Clinical Gastroenterology and Hepatology (2018)
Prospective observational cohort study of oesophagogastric cancer patients (POCOP): A Dutch nationwide cohort
Authors: J.J. van Kleef, L.V. van de Poll-Franse, R.H. Verhoeven, M. Slingerland, J.P. Ruurda, J. Heisterkamp, C. Rosman, J.W.B. de Groot, E.A. Kouwenhoven, M.A. van Dijk, E. de Graaf, T. van Voorthuizen, F. Daams, S. Lagarde, G.A.P. Nieuwenhuijzen, J. Vincent, M. van Berge Henegouwen, M.G.H. van Oijen, M.A.G. Sprangers, H.W.M. van Laarhoven
Journal: Annals of Oncology (2018)
Management of leptomeningeal metastases in EGFR mutated non-small cell lung cancer: Analysis of tyrosine kinase inhibitors sequence
Authors: R. Flippot, E. Auclin, P. Biondani, E. Le Rhun, J. Adam, D. Planchard, C. Caramella, C. Le Pechoux, L. Lacroix, A. Gazzah, L. Mezquita, B. Besse
Journal: Annals of Oncology (2018)
Tumor regression grading after preoperative hyperfractionated radiotherapy/chemoradiotherapy for locally advanced rectal cancers: A phase III clinical study
Authors: A. Idasiak, K. Galwas-Kliber, K. Behrendt, I. Wziętek, M. Zeman, E. Stobiecka, E. Chmielik, T. Dworzecki, R. Suwiński
Journal: Annals of Oncology (2018)
P2.01-60 Clinical Utility of Circulating Tumor Cell (CTC) Analysis Using Target Selector™ in Metastatic NSCLC Chemotherapy Patients
Authors: L. Kujtan, C.R. Vibat, V. Singh, K. Kennedy, A. Shrestha, S. Madhusudhana, J. Smeltzer, A. Masood, J. Subramanian
Journal: Journal of Thoracic Oncology (2018)
Autofluorescence: A new marker for identifying cancer stem cells (CSCs) in primary tumors
Authors: M. López Gómez, E. Casado, M. Muñoz, S. Alcalá, J. Moreno-Rubio, S. Salinas, F. Zambrana, A.M. Jiménez-Gordo, B. Sainz
Journal: Annals of Oncology (2018)
P1.01-65 PII of Pemetrexed or Pemetrexed Plus Bevacizumab for Previously Untreated Elderly (&gt;=75) Non-Squamous NSCLC (LOGIK1201)
Authors: R. Maruyama, M. Fukuda, T. Kitazaki, D. Ogawara, M. Ichiki, H. Mukae, N. Nakagaki, J. Kishimoto, Y. Ichinose, K. Sugio
Journal: Journal of Thoracic Oncology (2018)
Ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive locally advanced or metastastic esophagogastric adenocarcinoma (EGA): The randomized phase II INTEGA trial (AIO STO 0217)
Authors: E. Goekkurt, M. Binder, S. Lorenzen, P.C. Thuss-Patience, S.-E. Al-Batran, A. Hinke, S. Hegewisch-Becker, S. Nilsson, C. Bokemeyer, A. Stein
Journal: Annals of Oncology (2018)
Short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): A planned interim analysis
Authors: J. Jin, Y. Tang, S. Liu, Y. Zhu, W. Wang, G. Li, X. Wang, J. Wang, J. Yang, S. Li, N. Li, W. Liu, Y. Li, Y. Chi, A. Zhou, J. Huang, X. Wang, L. Jiang, J. Jiang, S. Zou
Journal: Annals of Oncology (2018)
P3.13-25 Development of a Comprehensive Genomic Profiling System to Detect Actionable Genetic Alterations and Tumor Mutation Burden
Authors: S. Jones, S. Angiouli, K. Gerding, L. Keefer, J. Hernandez, J. White, J. Simmons, F. Cavallo, M. Sausen
Journal: Journal of Thoracic Oncology (2018)
ERS statement on harmonised standards for lung cancer registration and lung cancer services in Europe
Authors: Anna L. Rich, David R. Baldwin, Paul Beckett, Thierry Berghmans, Jeanette Boyd, Corinne Faivre-Finn, Françoise Galateau-Salle, Fernando Gamarra, Bogdan Grigoriu, Niels-Christian G. Hansen, Georgia Hardavella, Erik Jakobsen, Dragana Jovanovic, Assia Konsoulova, Gilbert Massard, John McPhelim, Anne-Pascale Meert, Robert Milroy, Luciano Mutti, Marianne Paesmans, Michael D. Peake, Paul Martin Putora, Dirk K.M. de Ruysscher, Jean-Paul Sculier, Arnaud Schepereel, Dragan R. Subotic, Paul Van Schil, Torsten Gerriet Blum
Journal: European Respiratory Journal (2018)

The European Respiratory Society (ERS) task force for harmonised standards for lung cancer registration and lung cancer services in Europe recognised the need to create a single dataset for use in pan-European data collection and a manual of standards for European lung cancer services. The multidisciplinary task force considered evidence from two different sources, reviewing existing national and international datasets alongside the results of a survey of clinical data collection on lung cancer in 35 European countries. A similar process was followed for the manual of lung cancer services, with the task force using existing guidelines and national or international recommendations for lung cancer services to develop a manual of standards for services in Europe. The task force developed essential and minimum datasets for lung cancer registration to enable all countries to collect the same essential data and some to collect data with greater detail. The task force also developed a manual specifying standards for lung cancer services in Europe. Despite the wide variation in the sociopolitical landscape across Europe, the ERS is determined to encourage the delivery of high-quality lung cancer care. Both the manual of lung cancer services and the minimum dataset for lung cancer registration will support this aspiration.
Phase II trial evaluating olaparib maintenance in patients with MCRPC after docetaxel treatment reaching partial or stable response
Authors: M.J. Juan Fita, L. Heras Lopez, B. Mellado, M.J. Mendez Vidal, U. Anido, D. Lorente, J.M. Sepulveda, C. Alvarez
Journal: Annals of Oncology (2018)
CTC-based biomarkers &amp; PSMA-targeted imaging in patients with metastatic castrate-resistant prostate cancer (mCRPC)
Authors: M.J. Morris, N.J. Vogelzang, O. Sartor, A. Armour, R. Messmann, M. Groaning, A. Robarts, A.W. Tolcher, M. Gordon, H.M. Babiker, P. Kuo, M. Kearney, A. Jendrisak, Y. Wang, M. Landers, D.P. Petrylak
Journal: Annals of Oncology (2018)
Physical activity (PA) and patterns of quality of life (QOL) after adjuvant chemotherapy (CT) for breast cancer (BC)
Authors: A. Di Meglio, M. El-Mouhebb, S. Michiels, D. Carene, S. Everhard, A.L. Martin, P.H. Cottu, F. Lerebours, C. Coutant, A. Lesur, O. Tredan, P. Soulie, L. Vanlemmens, P. Arveux, S. Delaloge, P. Ganz, F. André, A.H. Partridge, L. Jones, I. Vaz-Luis
Journal: Annals of Oncology (2018)
Association of immune-related adverse (irAEs) with immune-checkpoint inhibitors (ICIs) efficacy in solid tumors
Authors: M. Riudavets Melia, L.P. del Carpio, I. Gabriela Sullivan, A. Barba Joaquín, P. Maroto Rey, G. Anguera Palacios, D. Páez López-Bravo, A. Callejo Pérez, C. González Blanco, D. Castillo Villegas, C. Facundo Molas, E. Garcia Planella, I. Genua Trullos, A. López Pousa, A. Sebio García, C. Martín Lorente, A.C. Virgili Manrique, O. Gallego Rubio, A. Barnadas Molins, M. Majem Tarruella
Journal: Annals of Oncology (2018)
Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients
Authors: J. Specht, L. Pusztai, A. Forero-Torres, M. Mita, A. Weise, I. Krop, A. Grosse-Wilde, Z. Wang, M. Li, S. Hengel, P. Garfin, G. Means, M. Onsum, S. Modi
Journal: Annals of Oncology (2018)
P1.16-02 Support and Information Needs for Patients with NSCLC Receiving Concurrent Chemo-Radiotherapy: Findings from the INSIGHT Study
Authors: J. Fenemore, G. Punnett, J. Yorke, F. Blackhall, D. Mcentee, M. Eaton, H. Neal
Journal: Journal of Thoracic Oncology (2018)
Novel online drug-drug interaction resource reveals clinically relevant interactions in &gt; 20% of the searches
Authors: N.A.G. Lankheet, K.R.M. Ferrier, S.E. Gibbons, D.M. Burger, K. McAllister, J.L.M. Martin, S.H. Khoo, N. van Erp, F.G. Jansman
Journal: Annals of Oncology (2018)
MA23.02 Circulating Tumor DNA Analysis with a Novel Variant Classifier for Recurrence Detection in Resected, Early-Stage Lung Cancer
Authors: V. Lam, H. Tran, M. Vasquez, K. Li, K. Yuen, F. Vang, A. Jaimovich, D. Kennedy, J. Odegaard, S. Mortimer, S. Olsen, V. Raymond, A. Vaporciyan, M.B. Antonoff, G. Walsh, E. Roarty, L. Lacerda, J. Roth, S. Swisher, C. Bernatchez, B. Sepesi, D. Gibbons, J. Zhang, J. Heymach
Journal: Journal of Thoracic Oncology (2018)
Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer
Authors: C.-C. Lin, M. Taylor, V. Boni, P.F. Brunsvig, S.L. Geater, S. Salvagni, P. Garrido Lopez, M. Özgüroğlu, V. Sriuranpong, S. Ponce Aix, P.A. Ascierto, A. Fasolo, A. Sezer, D.M. Kowalski, J.E. Faris, S. Cameron, J. Mataraza, H. Wu, V. Antona, M. Ochoa de Olza
Journal: Annals of Oncology (2018)
REVEAL: A phase I/II, open-label, multicenter, dose escalation and dose expansion study of NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] with or without nivolumab (nivo) in patients (pts) with locally advanced or metastatic solid tumor malignancies
Authors: A. Diab, M. Marcondes, M.A. Tagliaferri, U. Hoch, J. Zhang, W. Rubas, S. Kivimae, J. Zalevsky, A.P. Conley, E. Borazanci, S.P. D'Angelo
Journal: Annals of Oncology (2018)
Human iPSC-derived blood-brain barrier microvessels: validation of barrier function and endothelial cell behavior
Authors: Raleigh M. Linville, Jackson G. DeStefano, Matt B. Sklar, Zinnia Xu, Alanna M. Farrell, Max I. Bogorad, Chengyan Chu, Piotr Walczak, Linzhao Cheng, Vasiliki Mahairaki, Katharine A. Whartenby, Peter A. Calabresi, Peter C. Searson
Journal: Biomaterials (2018)
P3.01-32 An Open-Label, Non-Randomized, Biomarker Study of Concordance in Non-Invasive and Tissue Tests for T790M Detection in NSCLC
Authors: J. Gregg, C. Baik, M. Dietrich, S. Dubinett, D. Gerber, H. Husain, M. Shiller, M. Miranda, N. Chehab, H. West
Journal: Journal of Thoracic Oncology (2018)
Microsatellite instability detection by targeted sequencing of cell-free DNA
Authors: A. Artyomenko, M. Sikora, M. Lefterova, V.M. Raymond, D. Gavino, C. Barbacioru, C. Artieri, E. Helman, D. Chudova, R.B. Lanman, J. Odegaard, J.A. Willis, M. Fakih, S. Kopetz, A. Talasaz
Journal: Annals of Oncology (2018)
MA25.03 Defining Oligometastatic Non-Small Cell Lung Cancer (NSCLC): An Evolving Multidisciplinary Expert Opinion
Authors: L. Hendriks, C. Dooms, T. Berghmans, S. Novello, A. Levy, D. De Ruysscher, B. Hasan, M. Giaj Levra, N. Giaj-Levra, B. Besse, J. Vansteenkiste, A. Dingemans
Journal: Journal of Thoracic Oncology (2018)
P3.01-73 Talc Versus Minocycline and OK-432 Pleurodesis for Malignant Pleural Effusion.
Authors: E. Mochizuki, Y. Mochizuka, K. Oishi, H. Naoi, S. Matsuura, S. Mikura, M. Nagaoka, M. Tsukui, N. Koshimizu
Journal: Journal of Thoracic Oncology (2018)
PD-1 Blockade in Early-Stage Lung Cancer
Authors: Samuel Rosner, Joshua E. Reuss, Patrick M. Forde
Journal: Annual Review of Medicine (2018)

Early-stage non-small cell lung cancer is a potentially curable disease, but with relapse rates exceeding 50% with standard treatments, this is a patient population in critical need of therapy innovation. Immunotherapy with immune checkpoint blockade has revolutionized the treatment strategy for advanced lung cancer. However, the role of this therapy in earlier-stage disease is largely unknown. The study of immunotherapy in earlier-stage disease has many advantages, including assessment of pathologic response and incorporation of translational scientific analyses to evaluate antitumor immune responses. Multiple clinical trials are currently under way, with promising early results.
P3.03-05 Comparative Transcriptomic Analysis of Lung-iPSC, NSCLC, and SCLC: Potential Implications for iPSC Modeling of Lung Cancer
Authors: V. Shukla, K. Mcloughlin, J. Gao, Y. Wang, J. Hong, M. Zhang, L. Gesumaria, H. Chen, D. Schrump
Journal: Journal of Thoracic Oncology (2018)
MA27.03 Multi-Omic Characterization of TKI-Treated Drug-Tolerant Cell Population in an EGFR-Mutated NSCLC Primary-Derived Xenograft
Authors: E. Stewart, M. Cabanero, V. Raghavan, J. Bruce, P. Guilhamon, R. Singhania, N. Pham, S.Y. Shen, T. Li, M. Li, N. Leighl, F. Shepherd, T. Pugh, D. De Carvalho, M. Lupien, G. Liu, M. Tsao
Journal: Journal of Thoracic Oncology (2018)
Meta-analysis of biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer
Authors: K. Nishikawa, W. Koizumi, A. Tsuburaya, T. Yamanaka, S. Morita, K. Fujitani, Y. Akamaru, K. Shimada, H. Hosaka, N. Nakayama, Y. Miyashita, T. Tsujinaka, J. Sakamoto
Journal: Annals of Oncology (2018)
Management and outcome of metastatic breast cancer in men in the national multicenter observational ESME program
Authors: J. Sirieix, J. Fraisse, S. Mathoulin-Pelissier, M. Leheurteur, L. Vanlemmens, C. Jouannaud, V. Dieras, C. Levy, F. Dalenc, M.-A. Mouret-Reynier, T. Petit, B. Coudert, E. Brain, B. Pistilli, J.-M. Ferrero, A. Gonçalves, L. Uwer, S. Gourgou, J.-S. Frenel
Journal: Annals of Oncology (2018)
The incidence of recurrent venous thromboembolism (VTE) and bleeding depending on practical treatment pattern of anticoagulation in the cancer patients with VTE
Authors: S.-M. Bang, J.-H. Kang, M.H. Hong, J.S. Ahn, S.Y. Oh, J.H. Baek, Y.J. Choi, S.H. Shin, Y.-J. Kim, J.-H. Cha, J. Lee
Journal: Annals of Oncology (2018)
Loss of GTPase of immunity-associated protein 5 (Gimap5) promotes pathogenic CD4+ T-cell development and allergic airway disease
Authors: Andrew R. Patterson, Paige Bolcas, Kristin Lampe, Rachel Cantrell, Brandy Ruff, Ian Lewkowich, Simon P. Hogan, Edith M. Janssen, Jack Bleesing, Gurjit K. Khurana Hershey, Kasper Hoebe
Journal: Journal of Allergy and Clinical Immunology (2018)
Antiviral therapy improves outcomes after radiofrequency ablation for HBV-related hepatocellular carcinoma: A propensity score matching analysis
Authors: K. Wang, F. Shen, J. Liu, Z. Yan, J. Li, Y. Xia, L. Shi, G. Qian, Z. Lu, Y. Chen, X. Wan, M. Wu, Y. Zhang
Journal: Annals of Oncology (2018)
Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation
Authors: S. Viteri, G.-C. Chang, R. Chiari, B.C. Cho, F. Ciardiello, G. Curigliano, T. Hida, D.H. Lee, W.T.D. Lim, C.-C. Lin, A. Martinez, H. Murakami, I. Natsume, M. Nishio, L. Paz-Ares, R.A. Soo, V. Cattan, E. Gandossi, H. Heck, K. Park
Journal: Annals of Oncology (2018)
Prospective evaluation of regorafenib dose escalation strategy with low starting dose in patients with colorectal cancer
Authors: T. Masuishi, T. Suzuki, Y. Sukawa, C.K. Imamura, H. Satake, Y. Kumekawa, S. Funakoshi, M. Kotaka, Y. Horie, S. Kawai, H. Okuda, T. Terazawa, C. Kondoh, K. Kato, K. Yoshimura, H. Ishikawa, Y. Hamamoto, N. Boku, T. Kanai, H. Takaishi
Journal: Annals of Oncology (2018)
P1.04-08 Co-Residence of Patient-Derived Immune Cells in Patient-Derived Xenografts from Lung Cancer Patients
Authors: X. Pu, R. Zhang, L. Wang, A. Pataer, I.M. Meraz, X. Zhang, S. Wu, Y. Chen, L. Wu, D. Su, W. Mao, J. Heymach, J.A. Jack A. Roth, S. Swisher, B. Fang
Journal: Journal of Thoracic Oncology (2018)
Magnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA)
Authors: C. Molto Valiente, M. Borrell, A. Ocana Fernandez, A.J. Templeton, L.P. del Carpio, J. Del Paggio, A. Barnadas, C.M. Booth, A. Tibau, E. Amir
Journal: Annals of Oncology (2018)
Prostate-Specific Membrane Antigen–Positive Manifestations of Chronic Beryllium Lung Disease
Authors: Kai Huang, Alexander DJ Baur, Christian Furth
Journal: Clinical Nuclear Medicine (2018)

Three years after prostatectomy, a 78-year-old man with initial high-risk prostate cancer and new increasing prostate-specific antigen levels underwent Ga-prostate-specific membrane antigen (PSMA) PET/CT. Imaging revealed PSMA-positive pelvic, ascending retroperitoneal and left supraclavicular lymph nodes consistent with metastases. Additionally, there was PSMA-positive lymphadenopathy (hilar and mediastinal) and pulmonary changes (fibrotic and nodular) in which histopathology excluded metastases. A lymphocyte proliferation test was indicative of beryllium sensitization. Chronic beryllium lung disease-a multisystem granulomatous inflammatory disease mainly affecting the lungs-could be established in this patient with occupational exposure to beryllium. This case shows that manifestations of berylliosis can also be PSMA positive.
P1.03-12 PD-L1 Expression is Predominant in CD68+ Tumor-Associated Macrophages in Stage I-III Non-Small Cell Lung Cancers
Authors: B. Sepesi, L. Federico, K. Mitchell, E. Parra, A. Francisco Cruz, A. Ravelli, C. Haymaker, T. Karpinets, T. Cascone, A. Weissferdt, M.B. Antonoff, G. Walsh, C. Bernatchez, J. Roth, J. Zhang, E. Roarty, L.C.A.D.L. Landry, A. Vaporciyan, S. Swisher, J. Heymach, I. Wistuba, D. Gibbons
Journal: Journal of Thoracic Oncology (2018)
P3.01-47 Clinical Characteristics and Outcome for Patients with Advanced Lung Adenocarcinoma Treated with First-Line Pemetrexed Plus Platinum
Authors: X. Ji, X. Hu, Y. Zhu, Y. Liu, L. Lin, P. Xing, X. Hao, Y. Wang, J. Li
Journal: Journal of Thoracic Oncology (2018)
P1.01-62 The Third Generation Irreversible EGFR Inhibitor HS-10296 in Advanced Non-Small Cell Lung Cancer Patients
Authors: S. Lu, R. Camidge, C. Yang, J. Zhou, R. Guo, C. Chiu, G. Chang, H. Shiah, Y. Chen, C. Wang, D. Berz, W. Su, N. Yang, Z. Wang, J. Fang, J. Chen, P. Nikolinakos, Y. Lu, H. Pan, A. Maniam, L. Bazhenova, K. Shirai, M. Jahanzeb, M. Willis, N. Masood, N. Chowhan, T. Hsia, J.C. Yang
Journal: Journal of Thoracic Oncology (2018)
JAVELIN renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC)
Authors: R.J. Motzer, K. Penkov, J.B.A.G. Haanen, B.I. Rini, L. Albiges, M.T. Campbell, C.K. Kollmannsberger, S. Negrier, M. Uemura, J.L. Lee, H. Gurney, R. Berger, M. Schmidinger, J. Larkin, M.B. Atkins, J. Wang, P.B. Robbins, A. Chudnovsky, A. Di Pietro, T.K. Choueiri
Journal: Annals of Oncology (2018)